President Joe Biden has picked Brendan Danaher, a former Department of Transportation aide and longtime union official, as his new top labor policy adviser.

B. Braun Medical Inc. used objectively prudent procedures to manage its $790 million 401(k) plan for over 6,600 participants, a federal trial court said.

Hedge fund firm Sculptor Capital Management Inc. said its deal to be acquired by Rithm Capital Corp. will cut Chief Executive Officer Jimmy Levin’s pay, a flash point in the long-running dispute between the publicly traded hedge fund firm and its founder.

The makeup of the NLRB board remains in flux as Congress prepares to vote on the Democrats’ nominee while still awaiting a candidate for the open Republican seat on the five-member board. Meanwhile, a New York state law aimed to promote pay transparency goes into effect next month.

Novo Nordisk’s recent announcement that its blockbuster obesity drug Wegovy reduced heart disease risk is prompting employers to look into covering pricey weight-loss drugs.

The drugmakers suing the US government in multiple courts to block drug price negotiations are doing so for good reason—they’re the ones that stand to lose the most in Medicare’s first-ever plan to control the cost of medicines it spends the most on.